Hyrimoz Alternatives in Alaska
Compare generic and therapeutic alternatives to Hyrimoz (adalimumab-adaz (biosimilar)) available at Alaska pharmacies. Save up to 84% on your prescription — no insurance required.
Top Alternatives in Alaska
Hadlima (adalimumab biosimilar)
generic
Alternative interchangeable Humira biosimilar
Avg cash price: $1200/mo
Humira (brand adalimumab)
brand
Reference biologic — same molecule at significantly higher cost
Avg cash price: $6800/mo
Methotrexate
therapeutic
Non-biologic DMARD — dramatically cheaper first-line option
Avg cash price: $30/mo
Alaska Prescription Assistance Programs
Alaska Senior Benefits Program
Monthly cash payments to low-income seniors that can be applied toward prescription costs and other needs.
Eligibility: Alaska residents aged 65+ with income at or below 175% of the federal poverty level.
Frequently Asked Questions
What is Hyrimoz and how does it compare to Humira?
Hyrimoz (adalimumab-adaz) is an FDA-approved biosimilar to Humira, manufactured by Sandoz. It is rated interchangeable in the US — meaning pharmacists can substitute it without a new prescription in participating states.
Is Hyrimoz citrate-free?
Yes — the high-concentration formulation of Hyrimoz (100 mg/mL) is citrate-free. Citrate-free adalimumab formulations are associated with less injection site pain compared to older Humira formulations.
What is the difference between Hyrimoz and Hadlima?
Both are interchangeable adalimumab biosimilars. Hyrimoz is made by Sandoz; Hadlima by Samsung Bioepis. Clinical outcomes are equivalent. Price and formulary placement differ by payer.
Why would my doctor switch me from Humira to Hyrimoz?
The main reason is cost — biosimilars can save patients and insurers thousands per month. If you are stable on Humira, switching to an interchangeable biosimilar like Hyrimoz is clinically appropriate in most cases.
Can Script Unlock help me access Hyrimoz?
Specialty pharmacies in the Script Unlock network may carry Hyrimoz. Posting your prescription allows specialty pharmacies to submit competitive bids for biosimilar adalimumab products.